Spectral Diagnostics (EDTXF) Projected to Post Quarterly Earnings on Thursday

Spectral Diagnostics (OTCMKTS:EDTXF) is anticipated to announce its results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.0073) per share and revenue of $0.5410 million for the quarter.

Spectral Diagnostics Stock Up 12.4%

OTCMKTS:EDTXF opened at $1.07 on Wednesday. Spectral Diagnostics has a 12-month low of $0.47 and a 12-month high of $1.31. The stock’s fifty day simple moving average is $0.97 and its 200-day simple moving average is $1.00. The firm has a market capitalization of $312.45 million, a P/E ratio of -9.71 and a beta of 0.04.

About Spectral Diagnostics

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.